Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FLT3-ITD mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FLT3 amplification (1)

FLT3 amplification (1)

›

Related tests:

LeukoStrat® CDx FLT3 Mutation Assay (6)

LeukoStrat® CDx FLT3 Mutation Assay (6)

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine Resistant: B - Late Trials cytarabine Resistant : B	cytarabine Resistant: B - Late Trials cytarabine Resistant : B
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B	venetoclax + azacitidine Sensitive: B - Late Trials venetoclax + azacitidine Sensitive : B
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2	ponatinib Sensitive: C2 – Inclusion Criteria ponatinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2	TP-0903 Sensitive: C2 – Inclusion Criteria TP-0903 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C2 – Inclusion Criteria venetoclax + gilteritinib Sensitive : C2	venetoclax + gilteritinib Sensitive: C2 – Inclusion Criteria venetoclax + gilteritinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2	PHI-101 Sensitive: C2 – Inclusion Criteria PHI-101 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2